Journal of Clinical Oncology
Articles in this Issue
Phase 3 clinical trial of the combination of erlotinib plus ramucirumab compared with osimertinib in untreated advanced or recurrent non-small cell lung cancer with EGFR L858R mutation: The REVOL858R trial (WJOG14420L).
LBA8518 Background: Among common EGFR-mutant NSCLC, L858R mutation is suggested to be less sensitive to EGFR-TKIs and asso...
Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab versus conventional short-course preoperative chemoradiotherapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (mRCAT-III): A multicenter, randomized, open-label, phase 3 trial.
LBA3515 Background: Total neoadjuvant chemoradiotherapy is the standard of care for locally advanced rectal cancer (LARC)...
Adjuvant hepatic arterial infusion pump chemotherapy with floxuridine for patients with resectable colorectal liver metastases and a low clinical risk score: A randomized controlled trial—The PUMP trial.
LBA3506 Background: Recurrence after local treatment for colorectal liver metastases (CLM) occurs in up to 70% of patients...
frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
LBA7000 Background: ~40% of DLBCL pts are not cured with first-line (1L) R-CHOP, underscoring a significant unmet need for...
Role of neoadjuvant versus adjuvant chemotherapy, dose density, and treatment schedule in biologically high-risk HR+/HER2- breast cancer: A pooled analysis of the WSG ADAPT-HR+/HER2- and PlanB trials.
LBA515 Background: Dose-dense anthracycline-taxane chemotherapy (CTx) is standard for high-risk early breast cancer (eBC)...
Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.
LBA1000 Background: In ASCENT-04, first-line (1L) SG + pembro led to a statistically significant and clinically meaningful...
Nationwide randomized, phase III, placebo-controlled trial of bupropion for cancer-related fatigue: Primary outcome results.
LBA12003 Background: Fatigue is common and debilitating among people with cancer. Treatment options for cancer-related fat...
Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.
LBA7506 Background: A growing number of patients (pts) entering second-line treatment (tx) are anti-CD38 monoclonal antibo...
Darovasertib plus crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial.
LBA9503 Background: Uveal melanoma (UM) is the most common ocular cancer in adults with up to 50% of patients developing m...
Disease-free survival (DFS) and time to recurrence (TTR) with circulating tumor (ct) DNA–based decision for adjuvant treatment in colon cancer stage II (CIRCULATE): An AIO (KRK-0217)/ABCSG trial.
LBA3500 Background: Adjuvant chemotherapy (ACT) provides limited benefit in unselected stage II colon cancer patients (pts...
A phase III CHIPRO study of chiauranib plus weekly paclitaxel for platinum-resistant or refractory ovarian cancer.
LBA5504 Background: Platinum-resistant or refractory ovarian cancer is associated with poor prognosis and has limited trea...
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
LBA2 Background: Dedifferentiated liposarcoma (DDLS) remains a difficult disease to treat with limited systemic therapy op...
Efficacy and safety of fruquintinib combined with chemotherapy versus bevacizumab combined with chemotherapy as second-line treatment for metastatic colorectal cancer: A prospective, multicenter, randomized controlled trial.
LBA3563 Background: The optimal second-line treatment for metastatic colorectal cancer (mCRC) after failure of oxaliplatin...
ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases.
LBA9504 Background: Merkel cell carcinoma (MCC) with lymph node (LN) metastases (mets) is historically associated with hig...
First-line (1L) camizestrant (CAMI) for emergent <i>ESR1</i> mutations ( <i>ESR1</i> m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial.
LBA1007 Background: CAMI is a next-generation SERD and complete ER antagonist. SERENA-6 enrolled patients (pts) with HR+/H...
Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study).
LBA101 Background: Persistent plasma ctDNA EGFR mutations (EGFRm) at 3 weeks after first-line osimertinib predict poor out...
Izalontamab brengitecan (iza-bren) versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study.
LBA1003 Background: Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its aggressive biology and...
SUPPORT+ digital self-management and clinical support for advanced cancer: A randomized controlled trial.
LBA12008 Background: Patients with advanced cancer often experience distressing symptoms that impair HRQoL and lead to eme...
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.
LBA5 Background: Available 2L therapies offer limited clinical benefit in mPDAC with reported mPFS of 3–4 mo and mOS of 6–...
BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
LBA3503 Background: Leucovorin/5-FU in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are common chemothera...
A randomized, open-label, parallel-controlled phase 3 trial of benmelstobart plus chemotherapy and anlotinib for first-line treatment of advanced non-squamous non–small cell lung cancer.
LBA8507 Background: PD-1/PD-L1 inhibitors plus chemotherapy remain standard first-line therapy for EGFR/ALK/ROS1-wild type...
Ramelteon for prevention of postoperative delirium in elderly cancer patients: A randomized, double-blind, placebo-controlled multicenter trial, JORTC-PON02/J-SUPPORT2103/NCCH2103.
LBA12002 Background: Delirium is a common and serious complication after major cancer surgery in older adults. Current gui...
Concurrent thoracic radiotherapy (TRT), platinum/etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage (ES) small cell lung cancer (SCLC): A phase III trial.
LBA8005 Background: A phase III trial indicated a survival benefit of TRT after chemotherapy in ES SCLC. A synergistic eff...
Event-free survival with adjuvant selpercatinib in stage IB-IIIA <i>RET</i> fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial.
LBA3 Background: Selpercatinib, a highly selective, potent and brain-penetrant RET...
Ultra-low-dose immunotherapy plus oral metronomic chemotherapy versus paclitaxel-carboplatin in platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma: A randomized phase III trial.
LBA6007 Background: Standard first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNS...